Literature DB >> 18790954

Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.

B G Baumert1, R Stupp.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790954     DOI: 10.1093/annonc/mdn434

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  Integration of epidemiology, immunobiology, and translational research for brain tumors.

Authors:  Hideho Okada; Michael E Scheurer; Saumendra N Sarkar; Melissa L Bondy
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 2.  Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.

Authors:  Harsha Prasada Lashkari; Srdjan Saso; Lucas Moreno; Thanos Athanasiou; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2011-07-05       Impact factor: 4.130

3.  Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy.

Authors:  Seth A Climans; Warren P Mason; Eva Grunfeld; Kelvin Chan
Journal:  J Neurooncol       Date:  2022-08-06       Impact factor: 4.506

Review 4.  Management of low-grade glioma.

Authors:  Nader Pouratian; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

Review 5.  Low-grade gliomas.

Authors:  Deborah A Forst; Brian V Nahed; Jay S Loeffler; Tracy T Batchelor
Journal:  Oncologist       Date:  2014-03-24

6.  Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas.

Authors:  F Dhermain; G Saliou; F Parker; P Page; K Hoang-Xuan; C Lacroix; E Tournay; J Bourhis; D Ducreux
Journal:  J Neurooncol       Date:  2009-08-29       Impact factor: 4.130

7.  Cognitive Functions in Repeated Glioma Surgery.

Authors:  Gabriele Capo; Miran Skrap; Ilaria Guarracino; Miriam Isola; Claudio Battistella; Tamara Ius; Barbara Tomasino
Journal:  Cancers (Basel)       Date:  2020-04-26       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.